The internet is full of false claims. Columnist Sam Kirton shares why fact-checking is important, particularly for the rare disease world.

Hospitals in the USA are overwhelmed with a surge in patients due to a 'quad-demic' of flu, Covid-19, RSV, and norovirus. This unprecedented influx is ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Notable medicines subject to price increases include Pfizer’s COVID-19 drug Paxlovid, Bristol Myers Squibb’s CAR-T therapies Abecma and Breyanzi and a clutch of vaccines from Sanofi ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...

Pfizer targets $4 billion in operational savings by 2024, improving margins and driving long-term profitability. PFE returned $7.1 billion via dividends in 9M-24, while reducing debt by $4.4 ...

Sangamo Therapeutics (NASDAQ:SGMO) lost nearly half of its market cap in early trading on Tuesday after Pfizer (NYSE:PFE) decided to end a collaboration with the company for its gene therapy ...

Strong performance in oncology and specialty products is fueling new growth at Pfizer. The stock's 6.3% dividend is well-funded, and management has just increased it. The bar is low for ...

Pfizer’s research partnership with Sangamo Therapeutics produced a hemophilia A gene therapy that reached FDA discussions about a regulatory submission. That’s as far as the alliance will go.

Pfizer decided to terminate the global collaboration and license agreement between the parties. Sangamo intends to explore all options to advance the program, including seeking a potential new ...

Pfizer Inc. defeated a lawsuit from Texas Attorney General Ken Paxton that alleged the pharmaceutical giant misrepresented the effectiveness of its Covid-19 vaccine. Pfizer is entitled to immunity ...

Pfizer has abandoned development of a hemophilia A gene therapy it licensed from Sangamo Therapeutics, a move that could imperil Sangamo’s future. It’s a sudden turnabout for Pfizer, which had ...